The usefulness of 5-HT6 antagonists in the treatment of cognitive disorders and more recently in obesity and feeding disorders is well documented. Keeping in mind the minimum pharmacophoric requirement needed for the 5-HT6 receptor binding, a new series of N1-arylsulfonyl (1H-indole-2-yl)-1-(piperazinyl) methanone derivatives were designed, synthesized and tested for their in-vitro affinity towards the 5-HT6 receptor.
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 15261 citations as per Google Scholar report